PALO ALTO, Calif., May 30, 2018 /PRNewswire/ -- Designed to expand the availability of high quality cancer care globallyand help save the lives of millions more cancer patients, treatments with Varian's (NYSE: VAR) Halcyon™ system have started at three different cancer centers in northern and southern Africa. Halcyon simplifies
The cancer centers now offering Halcyon treatments in Africa are Clinique le Littoral Casablanca and Centre d'Oncologie Nakhil Rabat in Morocco, and Busamed Oncology Center- Hillcrest in South Africa.
With the innovations in Halcyon, the system delivers high quality treatments, which empowers clinicians to care for more patients. Halcyon features a streamlined workflow that only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. To assist in the reduction of time and construction costs from installation to first patient treatment, Halcyon offers expedited commissioning, requires less shielding than traditional systems, can fit in the majority of existing small vaults and can be installed in two weeks or less. Several cancer centers have already begun treating patients with Halcyon including Radiation Oncology Centres (Australia), University Hospitals Leuven (Belgium), Queen's Hospital (England), and Penn Medicine (U.S.).
"We are proud of our collaboration with these centers in Africa and increasing the access to high quality cancer treatments with Halcyon," said Jean-LucDevleeschauwer, president, Varian Oncology Systems EMEIA. "We look forward to working with more centers across the region, and around the world, in the global fight against cancer."
About Varian Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Mark PlungyDirector, Public Relations+1 (650) firstname.lastname@example.org
Investor Relations Contact
J. Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163 email@example.com
View original content:http://www.prnewswire.com/news-releases/varian-halcyon-systems-expand-access-to-cancer-care-at-three-centers-in-africa-300655140.html
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All